AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Short-chain dehydrogenase/reductase 3

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

O75911

UPID:

DHRS3_HUMAN

Alternative names:

DD83.1; Retinal short-chain dehydrogenase/reductase 1; Retinol dehydrogenase 17; Short chain dehydrogenase/reductase family 16C member 1

Alternative UPACC:

O75911; B2R7F3; Q5VUY3; Q6UY38; Q9BUC8

Background:

Short-chain dehydrogenase/reductase 3, known by alternative names such as DD83.1, Retinal short-chain dehydrogenase/reductase 1, Retinol dehydrogenase 17, and Short chain dehydrogenase/reductase family 16C member 1, plays a crucial role in the visual cycle. It catalyzes the reduction of all-trans-retinal to all-trans-retinol in the presence of NADPH, a key step in the regeneration of the visual pigment rhodopsin.

Therapeutic significance:

Understanding the role of Short-chain dehydrogenase/reductase 3 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.